



PRESS RELEASE

Stockholm, 13 March 2024

CombiGene's epilepsy project CG01 has been granted patent in two new countries

CombiGene AB (publ) ("CombiGene", the "Company") today announces that the patent offices in Australia and India have granted patent for the epilepsy project CG01. The approval strengthens the project, which CombiGene recently has regained the global rights to.

CG01 has previously been granted patents in the USA and Russia.

"The fact that CG01 has been granted patent in two new countries strengthens the project as we are putting together an attractive proposition for a potential partner," says Karin Agerman, Chief Scientific Officer at CombiGene. "Finding a new partner for the epilepsy project is of high priority for CombiGene this year," Karin concludes.

About the epilepsy project CG01

CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.

About CombiGene AB

CombiGene's vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.

Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company's Certified Advisor is FNCA Sweden AB.

For more information, please contact:

CombiGene AB (publ)

Peter Ekolind, CEO

Tel: +46 (0)8-35 73 55

peter.ekolind@combigene.com

Please read "Ingeneious", a newsletter from CombiGene which contains general news and information that is deemed not to have a significant effect on the share price. Ingeneious and press releases are available at www.combigene.com.